BioSpace News Archive

Alpine Immune Sciences, Inc., a company focused on discovering and developing innovative, protein-based immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, and Laurel Venture Capital, a life science focused venture capital fund based in Hangzhou, Zhejiang China, today announced the completion of the sale and transfer of global rights to the S-Nitrosoglutathione Reductase assets from Alpine to Laurel Venture Capital.

Endo International plc will announce its second-quarter 2018 financial results on August 8, 2018

Updated VA policy provides expanded access for training to additional VA centers and private rehabilitation clinics through the Veterans Choice Program

Grant awarded by the AmerisourceBergen Foundation will support the pilot program

Legislation would strengthen the pipeline and stockpile of medical countermeasures vital to our nation’s safety and defense

Over five years in the making, The Rocky Mountain Regional VA Medical Center will open its doors to inpatient veterans on August 4, 2018.

Eli Lilly and Company (NYSE: LLY) today announced that new results from a number of studies across the company’s Alzheimer’s disease pipeline will be presented at the Alzheimer’s Association International Conference (AAIC) in Chicago, July 22-26, 2018. Nearly 30 oral and poster presentations will underscore Lilly’s focus on making a meaningful difference in the lives of people living with Alzheimer’s through clinical development and collaboration.

Company Expects to File IND Application in Late 2018.

Nathan Falk, M.D., will be the first program director for the Florida State University College of Medicine Family Medicine Residency Program at Winter Haven Hospital.

One of the ways that the U.S. Food and Drug Administration is working to address the opioid epidemic is by encouraging the development of opioid analgesic products that are harder to manipulate and abuse.